The Company plans to discontinue further clinical development of ganaxolone in TSC. Marinus Pharmaceuticals announced that its phase 3 trial of ganaxolone did not meet the primary end point for the ...

Most TSC caregivers plan to continue Epidiolex due to benefits like fewer seizures and improved cognition. New data at AES 2024 underscores Epidiolex's positive impact on TSC patients' health and well ...

Please provide your email address to receive an email when new articles are posted on . Survey responses reflected positive language and communication outcomes after cannabidiol use. Further ...

Claire Behan, Ph.D. candidate, Academic Unit of Neurology, Trinity College Dublin and Registered Advanced Nurse Practitioner Epilepsy, Neurology Department, St. James's Hospital and co-author, said, ...

– Age-range for all EPIDIOLEX indications expanded to include patients one year of age and older – – Third indication approved for EPIDIOLEX, the only FDA-approved Cannabidiol (CBD) medicine – ...

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced ...

Tuberous sclerosis complex is a multisystem disorder in which neurologic problems cause the greatest disability. High rates of mental retardation and autism spectrum disorders are associated with the ...

Primary endpoint showed a median 16.6% reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23) Secondary endpoint of 50% responder rate at 30.4%, ...

The National Health Service England confirmed Tuesday that starting this week, doctors can prescribe Jazz Pharmaceuticals JAZZ Epidiolex, a CBD-based medicine, to patients suffering from tuberous ...

In early childhood, a woman developed multiple red papules on the nose and cheeks with the appearance of angiofibromas (see Figure 1). As an adult, papules formed around her toes which were consistent ...